

Developed in 1998, the Amaxa™ Nucleofector™ Technology was introduced to the research market in 2001 as the first efficient non-viral transfection method for primary cells and hard-to-transfect cell lines. Since then the technology has evolved through constant innovation. Based on user feedback, our engineers and scientists have developed the new innovative Nucleofector devices. These systems are designed for maximum flexibility and enables Nucleofection of cells in several formats combined with advanced performance and convenience.



4D-Nucleofector™ System

- Allows 1-16 reactions per experiment
- Suitable for Nucleofection™ of 10⁴ 10⁷ cells
- Reaction volumes 20 μl and 100 μl



96-well Shuttle™ Add-On

- Allows 1-96 reactions per experiment
- Suitable for Nucleofection™ of 10⁴ 10⁶ cells
- Reaction volume 20 μl

The technical seminar focuses on:

- transfection into hard to transfect cells.
- siRNA screening.
- gene targeting using CRISPR/Cas9 or Zinc finger

 \langle Date \rangle May 12th (Tuesday) 15:00-16:00

≪Venue≫ Room C-016

If you have any requests please let us know. Nucleofector demo **using your cells** in your labo is of course welcome. American technical staff will instruct not only how to use Nucleofector but also how to treat cells before and after Nucleofection.